MetaCap

Protagonist Therapeutics (PTGX) vs Summit Therapeutics (SMMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protagonist Therapeutics (PTGX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 42.2% versus a loss of 38.5%. Over five years, PTGX leads with a +265.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.92 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PTGX+42.15%SMMT-38.54%
+92%+24%-45%
Nov 21, 20251 yearNov 20, 2026
PTGX+246.56%SMMT+85.98%
+526%+206%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PTGX versus SMMT key metrics
MetricPTGXSMMT
Share price$121.40$9.95
Market cap$7.92B$7.96B
1-day change-2.11%-5.87%
YTD return+39.00%-43.11%
1-year return+42.15%-38.54%
5-year return+265.00%+92.83%
P/E ratio (TTM)25.67—
Forward P/E348.79—
EPS (TTM)$4.73$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$46.02M—
Revenue growth (YoY)-89.41%—
Net income (latest FY)$-130.15M$-1.08B
Operating margin-343.63%—
Net margin-282.83%—
52-week high$160.81$29.23
52-week low$77.00$9.89
Distance from 52-week high-24.51%-65.96%
Analyst consensusstrong_buybuy
Avg. price target upside+50.21%+189.15%
Average volume668.45K6.68M
Shares outstanding65.27M799.76M
Employees149265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PTGX has outperformed SMMT by 80.7 percentage points over the past year.

About Protagonist Therapeutics

PTGX stock →

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

PTGX vs SMMT FAQ

Which is bigger, Protagonist Therapeutics or Summit Therapeutics?

Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.92B for Protagonist Therapeutics (PTGX).

Which stock has performed better over the past year, PTGX or SMMT?

PTGX returned +42.15% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Protagonist Therapeutics and Summit Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons